Pharming Group NV lost nearly 25 percent of its value March 20 on news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) was standing by its original decision to adopt a negative opinion on an application for its hereditary angioedema (HAE) drug Rhucin. (BioWorld International)